---
schema_version: "secwatch.filing_event.v1"
accession: "0000950170-24-056252"
form_type: "8-K"
ticker: "AURA"
cik: "0001501796"
company_name: "Aura Biosciences, Inc."
filed_at: "2024-05-09T23:59:59+00:00"
generated_at: "2026-06-02T05:35:48.758367+00:00"
event_type: "earnings"
sentiment: "neutral"
materiality_score: 0.55
calibrated_materiality_score: 0.55
confidence: "high"
source: SEC EDGAR
---

# Aura Biosciences Q1 2024 net loss $19.7M; cash $202.9M funds into H2 2026

## Summary
- Net loss of $19.7M for Q1 2024 vs $17.5M in Q1 2023; R&D spend $17.1M (up from $14.4M).
- Cash and marketable securities $202.9M as of March 31, 2024; expected to fund operations into H2 2026.
- Phase 3 CoMpass trial for small choroidal melanoma enrolling globally; target ~100 patients.
- Phase 1 bladder cancer trial enrolling; early data expected mid-2024; Fast Track designation from FDA.
- Appointed Conor Kilroy as General Counsel and Secretary.

## SEC filing metadata
- accession: 0000950170-24-056252
- form_type: 8-K
- ticker: AURA
- cik: 0001501796
- company_name: Aura Biosciences, Inc.
- filed_at: 2024-05-09T23:59:59+00:00
- event_type: earnings
- sentiment: neutral
- materiality_score: 0.55
- calibrated_materiality_score: 0.55
- confidence: high
- sec_items: 2.02, 9.01
- EDGAR index: https://www.sec.gov/Archives/edgar/data/1501796/000095017024056252/0000950170-24-056252-index.htm
- EDGAR primary document: https://www.sec.gov/Archives/edgar/data/1501796/000095017024056252/aura-20240509.htm

## Machine-readable alternates
- HTML: https://secwatch.observer/filing/0000950170-24-056252
- JSON: https://secwatch.observer/filing/0000950170-24-056252.json
- Plain text: https://secwatch.observer/filing/0000950170-24-056252.txt

## Key facts
- Earnings Releases
  Aura Biosciences, Inc. reported financial results for first quarter ended March 31, 2024.
  - Period: first quarter ended March 31, 2024
  - Result: reported results
  source text: Aura Biosciences, Inc. issued a press release announcing its financial results for the quarter ended March 31, 2024.
  evidence_url: https://www.sec.gov/Archives/edgar/data/1501796/000095017024056252/0000950170-24-056252-index.htm

This AI-assisted summary is a reading aid. Review the linked SEC EDGAR filing before relying on any specific claim.